Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, ...

C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive ...

TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that ...

Not all probiotics are created equal. A new study found that one commonly available strain made a gut infection worse, while ...

COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid ...

Probiotic supplements are often consumed after antibiotic treatment to prevent antibiotic-associated diarrheal disease, most commonly caused by Clostridioides difficile (C. diff). However, the actual ...

Hepatitis C infections have been increasing in people with opioid use disorders. Within that population, men have been shown to be more likely to receive treatment for hepatitis C than women are.

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial for HCV treatment with bemnifosbuvir and ruzasvir.

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Role of high-dose vitamin C as adjunct treatment in gastric and colorectal cancers: A systematic review.. If you have the appropriate software installed, you can download article citation data to the ...

Learn the causes, symptoms, and treatment strategies for pseudomembranous colitis, a serious colon inflammation often triggered by antibiotics.

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV).